Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 22, 2021
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinomaMariona Riudavets, Joaquim Bosch-Barrera, Luís Cabezón-Gutiérrez, et al.
Investigational New Drugs|September 17, 2025
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumorsAlejandro Falcón, Santiago Ponce, Gregory M Cote, et al.
European Journal of Cancer Care|October 2, 2019
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancerEva María Ciruelos, María Nieves Díaz, María Dolores Isla, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 26, 2014
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancerC Vanesa Díaz-García, Alba Agudo-López, Carlos Pérez, et al.
Cancer|June 2, 2024
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancerFélix Blanc-Durand, Geraldine M Camilleri, Arnaud Bayle, et al.
Contemporary Oncology (Poznan, Poland)|February 26, 2024
High-dose alectinib for <i>RET</i> fusion-positive non-small cell lung cancer in the Blood First Assay Screening TrialRafal Dziadziuszko, Nir Peled, Tony Mok, et al.
Studies in Health Technology and Informatics|May 23, 2026
Modelling and Implementation of a Precision-Oncology Data-Integration Platform for Real-Word Molecular Tumor Borad Decision-MakingJulia Hernández-Pérez, Ángel Martínez-González, Sandra Cruz-Ballesteros, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Journal for Immunotherapy of Cancer|September 3, 2023
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironmentSantiago Ponce, Susana Cedrés, Charles Ricordel, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2019
Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patientsM Teresa Agulló-Ortuño, Inmaculada García-Ruiz, C Vanesa Díaz-García, et al.
Pageof 11